文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

估算血浆容量状态评估脓毒症早期液体复苏容量状态的可行性与预后价值

[Feasibility and prognostic value of estimated plasma volume status in assessing volume status during early fluid resuscitation in patients with sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论在脓毒症早期液体复苏中,估算血浆容量状态(ePVS)可能有助于评估容量状态,T6h静脉ΔePVS%升高是28天死亡的 protective 因素(OR=0.900)。

前瞻性研究纳入2023年3—12月昆明医科大学第一附属医院ICU的54例脓毒症患者(脓毒症17例、脓毒性休克37例),记录入ICU时及液体复苏前(T0h)、3小时(T3h)、6小时(T6h)的ePVS、ΔePVS%、下腔静脉直径与变异度、Pcv-aCO2、乳酸清除率等。28天存活34例、死亡20例,生存率63.0%。生存组T6h动脉和静脉ΔePVS%及白蛋白高于死亡组,SOFA评分、APACHE II评分、AST、T0h Lac、T3h和T6h去甲肾上腺素用量低于死亡组。T6h静脉ΔePVS%预测28天生存的AUC为0.726(95%CI 0.578-0.875,P=0.006),最佳截断值3.09%,敏感度82.4%、特异度60.0%;多因素Logistic回归显示T6h静脉ΔePVS%升高是28天死亡的 protective 因素(OR=0.900,95%CI 0.834-0.972,P=0.007)。作者认为ePVS可能具有评估脓毒症早期液体复苏容量状态的潜力,ΔePVS%可能有助于识别预后不良的脓毒症患者。

要点

  • 54例脓毒症患者中,脓毒性休克组入ICU时静脉ePVS低于脓毒症组[4.96(3.67, 7.15)dL/g vs. 7.55(4.36, 10.07)dL/g,P<0.05]。
  • 生存组T6h动脉ΔePVS%为11.57%(-1.82%, 31.35%)、静脉ΔePVS%为9.62%(3.59%, 25.75%),均高于死亡组的0.48%(-5.67%, 6.02%)和1.52%(-9.65%, 7.72%),均P<0.05。
  • T6h静脉ΔePVS%预测28天生存的AUC为0.726(95%CI 0.578-0.875,P=0.006),最佳截断值3.09%,敏感度82.4%、特异度60.0%。
  • 多因素Logistic回归显示T6h静脉ΔePVS%升高是28天死亡的 protective 因素(OR=0.900,95%CI 0.834-0.972,P=0.007)。
  • T6h静脉ePVS与T6h下腔静脉变异度呈正相关(r=0.360,P<0.05),T6h静脉ΔePVS%与T6h乳酸清除率呈正相关(r=0.286,P<0.05)。

适用人群与场景

  • 2023年3月至12月昆明医科大学第一附属医院ICU收治的脓毒症患者,最终分析54例,其中脓毒症17例、脓毒性休克37例。

诊断标准与关键阈值

  • 根据入ICU时诊断分为脓毒症组和脓毒性休克组;根据28天生存状态将脓毒症患者分为生存组和死亡组。

研究设计与关键结果

  • 前瞻性研究,纳入54例脓毒症患者,脓毒症17例、脓毒性休克37例;28天存活34例、死亡20例,28天生存率63.0%。
  • 脓毒性休克组入ICU时静脉ePVS低于脓毒症组[4.96(3.67, 7.15)dL/g vs. 7.55(4.36, 10.07)dL/g,P<0.05]。
  • 生存组较死亡组T6h动脉ΔePVS%[11.57%(-1.82%, 31.35%)vs. 0.48%(-5.67%, 6.02%)]、T6h静脉ΔePVS%[9.62%(3.59%, 25.75%)vs. 1.52%(-9.65%, 7.72%)]及白蛋白[27.57±4.15 g/L vs. 23.77±6.97 g/L]更高,均P<0.05。
  • 生存组较死亡组SOFA评分[9.00(8.00, 10.00)vs. 11.50(9.25, 14.50)]、APACHE II评分[18.00(14.75, 21.25)vs. 25.50(21.00, 30.00)]、AST[34.09(23.20, 56.64)U/L vs. 79.24(25.34, 196.59)U/L]、T0h Lac[1.75(1.40, 2.93)mmol/L vs. 3.25(2.33, 5.30)mmol/L]、T3h去甲肾上腺素用量[0.98(<0.01, 3.10)mg vs. 4.60(1.05, 8.55)mg]及T6h去甲肾上腺素用量[1.82(0.38, 5.30)mg vs. 8.20(2.80, 17.73)mg]更低,均P<0.05。
  • 两组其他基础资料及复苏前后各时间点ePVS差异无统计学显著差异。
  • 相关性分析:T6h静脉ePVS与T6h下腔静脉变异度呈显著正相关(r=0.360,P<0.05);T0h动脉ePVS与T3h和T6h液体入量呈显著负相关(r1=-0.367,r2=-0.280,均P<0.05);入ICU时静脉ePVS与入ICU时NT-proBNP呈显著正相关(r=0.409,P<0.05);T6h静脉ΔePVS%与T3h液体入量及T6h乳酸清除率呈显著正相关(r1=0.286,r2=0.286,均P<0.05),与T6h尿量及T6h Pcv-aCO2变化值(ΔPcv-aCO2)呈显著负相关(r1=-0.321,r2=-0.371,均P<0.05)。
  • ROC曲线分析:T6h静脉ΔePVS%预测脓毒症患者28天生存的AUC为0.726(95%CI 0.578-0.875,P=0.006),敏感度82.4%,特异度60.0%,最佳截断值3.09%。
  • 二分类多因素Logistic回归分析:T6h静脉ΔePVS%升高是脓毒症患者早期液体复苏28天死亡的 protective 因素(OR=0.900,95%CI 0.834-0.972,P=0.007)。

证据类型、等级与局限

  • 证据类型:前瞻性研究;局限性:原文未报告局限性。

对床旁实践的改变

  • 作者认为ePVS可能具有评估脓毒症患者早期液体复苏容量状态的潜力。
  • 作者认为早期液体复苏期间的ΔePVS%可能有助于识别预后不良的脓毒症患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the feasibility and prognostic implications of assessing volume status during early fluid resuscitation in septic patients based on estimated plasma volume status (ePVS).

METHODS: A prospective study was conducted. Patients with sepsis admitted to intensive care unit (ICU) of the First Affiliated Hospital of Kunming Medical University from March to December in 2023 were enrolled. The general information and laboratory indicators at ICU admission were recorded, and ePVS, sequential organ failure assessment (SOFA) score, acute physiology and chronic health status evaluation II (APACHE II) score were calculated. The vital signs, arterial blood gas analysis and volume status related indicators before liquid resuscitation (T0h) and 3 hours (T3h) and 6 hours (T6h) of fluid resuscitation were recorded. The diameter and variability of the inferior vena cava (IVC) were measured by ultrasound, and ePVS, percentage change value of estimated plasma volume status (ΔePVS%), difference in central venous-to-arterial partial pressure of carbon dioxide (Pcv-aCO2), and lactate clearance rate (LCR) were calculated. Patients were divided into sepsis group and septic shock group based on the diagnosis at ICU admission, and septic patients were subdivided into survival group and death group based on their 28-day survival status. The differences in clinical data between the groups were compared. The correlation between ePVS or ΔePVS% and volume status related indicators during early liquid resuscitation was analyzed by Spearman rank sum correlation test. The predictive value of each variable for 28-day survival in patients with sepsis was analyzed by receiver operator characteristic curve (ROC curve), and 28-day death risk factors were analyzed by Logistic regression method.

RESULTS: Fifty-four septic patients were enrolled in the final analysis, including 17 with sepsis and 37 with septic shock; 34 survived at 28 days and 20 died, with a 28-day survival rate of 63.0%. Compared with the sepsis group, the septic shock group had a lower venous ePVS at ICU admission [dL/g: 4.96 (3.67, 7.15) vs. 7.55 (4.36, 10.07), P < 0.05]. Compared with the death group, the survival group had higher T6h arterial and venous ΔePVS%, and albumin [Alb; T6h arterial ΔePVS% (%): 11.57% (-1.82%, 31.35%) vs. 0.48% (-5.67%, 6.02%), T6h venous ΔePVS%: 9.62% (3.59%, 25.75%) vs. 1.52% (-9.65%, 7.72%), Alb (g/L): 27.57±4.15 vs. 23.77±6.97, all P < 0.05], lower SOFA score, APACHE II score, AST, T0h Lac, and T3h and T6h norepinephrine dosage [SOFA score: 9.00 (8.00, 10.00) vs. 11.50 (9.25, 14.50), APACHE II score: 18.00 (14.75, 21.25) vs. 25.50 (21.00, 30.00), AST (U/L): 34.09 (23.20, 56.64) vs. 79.24 (25.34, 196.59), T0h Lac (mmol/L): 1.75 (1.40, 2.93) vs. 3.25 (2.33, 5.30), norepinephrine dosage (mg): 0.98 (< 0.01, 3.10) vs. 4.60 (1.05, 8.55) at T3h, 1.82 (0.38, 5.30) vs. 8.20 (2.80, 17.73) at T6h, all P < 0.05]. While there were no significantly differences in other basic data and ePVS at all of the time points before and after resuscitation between the two groups. Correlation analysis showed that T6h venous ePVS was significantly positively correlated with T6h IVC variability in septic patients (r = 0.360, P < 0.05), T0h arterial ePVS was significantly negatively correlated with T3h and T6h liquid intake volume (r1 = -0.367, r2 = -0.280, both P < 0.05), and venous ePVS at ICU admission was significantly positively correlated with NT-proBNP at ICU admission (r = 0.409, P < 0.05). T6h venous ΔePVS% was significantly positively correlated with T3h liquid intake volume and T6h LCR (r1 = 0.286, r2 = 0.286, both P < 0.05), and significantly negatively correlated with T6h urine volume and T6h change value of Pcv-aCO2 (ΔPcv-aCO2; r1 = -0.321, r2 = -0.371, both P < 0.05). ROC curve analysis showed that the area under the ROC curve (AUC) of T6h venous ΔePVS% for predicting 28-day survival in septic patients was 0.726 [95% confidence interval (95%CI) was 0.578-0.875, P = 0.006], with a sensitivity of 82.4%, a specificity of 60.0%, and an optimal cut-off value of 3.09%. Binary multifactorial Logistic regression analysis showed that an increase in T6h venous ΔePVS% was a protective factor for 28-day death in patients with sepsis on early fluid resuscitation [odds ratio (OR) = 0.900, 95%CI was 0.834-0.972, P = 0.007].

CONCLUSIONS: ePVS may have potential for assessing the volume status of septic patients during early fluid resuscitation. The ΔePVS% during early fluid resuscitation may help to identify septic patients with a poor prognosis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Liu X, Wang F, Xu W, et al. [Feasibility and prognostic value of estimated plasma volume status in assessing volume status during early fluid resuscitation in patients with sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41017174. doi:10.3760/cma.j.cn121430-20240729-00641

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。